Institutet för Hälso- och
Sjukvårdsekonomi
Box 2127
SE-220 02 Lund
Besök: Råbygatan 2
Tel: 046-32 91 00
ihe[at]ihe.se

Johansen Pierre
ekon mag | projektledare

Arbetsområden
Pierre har en ekon. mag. i nationalekonomi från Lunds Universitet samt en magisterexamen med huvudområde hälsoekonomi från Lunds Universitet.

Vid IHE arbetar Pierre främst med projekt rörande kostnadseffektivitet av Diabetes Mellitus (DM) typ 1 och 2-interventioner.

• Hälsoekonomiska utvärderingar
• Ekonomiska simuleringsmodeller 
  

Urval av publiceringar

Willis M, Johansen P, Nilsson A and Asseburg C
Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)
PharmacoEconomics 2017; 35(3): 375-96
Publicerad online: 12 november 2016 


Sabapathy S, Neslusan C, Yoong K, Teschemaker A, Johansen P & Willis M
Cost-effectiveness of Canagliflozin versus Sitagliptin when Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada
J Popul Ther Clin Pharmacol. 2016; 23(2): 151-168
July 15, 2016


Neslusan C, Teschemaker A, Johansen P, Willis M, Valencia-Mendoza A & Puig A
Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metforminin Patients with Type2 Diabetes Mellitus in Mexico
Value in health regional issues 2015; 8C: 8-19
Publicerad online: 3 juni 2015
http://dx.doi.org/10.1016/j.vhri.2015.01.002


Lundqvist A, Steen Carlsson K, Johansen P, Andersson E & Willis M
Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations
PLOS ONE 2014; 9(10): 1-12
Open access


Steen Carlsson K, Berne C, Johansen P, Lanne G & Gerdtham U-G
Behandling av diabetes i ett hundraårigt perspektiv
Fem rapporter om värdet av nya läkemedel.
Johanna Lind (red.)
Stockholm: SNS, februari 2013.


URVAL PRESENTATIONER

“Potential Importance of Capturing Cardiovascular Benefits Not Mediated by Traditional Risk Factors in T2DM Modeling: An Example Using Statins and the UKPDS 82 Outcomes Model”, Presented at Economics, simulation modelling & diabetes: The Mt Hood 2016 Challenge, St. Gallen, Switzerland, September 17-18, 2016. Johansen P, Willis M, Nilsson A, Asseburg C and Neslusan C

“The Role of Estimated Glomerular Filtration Rate (eGFR) in Cost-Effectiveness (CE) Analyses Using Canagliflozin (CANA) vs Sulfonylurea (SU) to Treat Type 2 Diabetes Mellitus (T2DM)”, Presented at ADA 76th Scientific Sessions, New Orleans, LA, USA, June 10-14, 2016, Neslusan C, Willis M, Johansen P, Schroeder M, Nilsson A, Chan E, Asseburg C, Schubert A

“Time Until Insulin Initiation for Canagliflozin (CANA) Versus Sitagliptin (SITA) in Dual Therapy and Triple Therapy for Type 2 Diabetes Mellitus (T2DM) in the UK”, Presented at ADA 76th Scientific Sessions, New Orleans, LA, USA, June 10-14, 2016, Schroeder M, Chan E, Willis M, Johansen P, Nilsson A, Schubert A, Neslusan C

“Time Until Insulin Initiation for Canagliflozin (CANA) Versus Dapagliflozin (DAPA) and Empagliflozin (EMPA) in Dual and Triple Therapy for Type 2 Diabetes Mellitus (T2DM) in the UK”, Presented at ISPOR 21st Annual International Meeting, Washington, WA, USA, May 21-25, 2016, Schroeder M, Chan E, Willis M, Johansen P, Nilsson A, Schubert A, Neslusan C

“Update of the Model Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)”, Presented at ISPOR 21st Annual International Meeting, Washington, WA, USA, May 21-25, 2016, Asseburg C, Willis M, Johansen P, Nilsson A, Neslusan C, Schroeder M

“Threshold-Based Metrics May Not Value All Benefits of Improved HbA1c: Implications for Health Care Resource Allocation”, Presented at International Diabetes Federation - World Diabetes Congress, Vancouver, Canada, November 30 – December 4, 2015, Willis M, Neslusan C, Martin S, Johansen P, Asseburg C, O’Brien D

“The Cost-Effectiveness of Canagliflozin (CANA) Versus Dapagliflozin (DAPA) 10mg and Empagliflozin (EMPA) 25mg in Patients with Type 2 Diabetes Mellitus (T2DM) as Monotherapy in the United Kingdom”, Presented at ISPOR 18th Annual European Congress, Milan, Italy, November 7-11, 2015, Schroeder M, Johansen P, Willis M, Neslusan C

“Cost of Achieving Combined Improvements in HbA1c and Weight without Hypoglycaemia over 4 Years in a Post-hoc Analysis of Dapagliflozin + MET vs. Glipizide + MET”, Presented at ISPOR 18th Annual European Congress, Milan, Italy, November 7-11, 2015, Johansen P, Mukherjee J, Sörstadius S, Sternhufvud C

“The Economic Consequences of Clinical Inertia in Treatment Intensification for Type 2 Diabetes Mellitus (T2DM) in the UK”, Podium Presentation at EASD 51st Annual Meeting, Stockholm, Sweden, September 14-18, 2015, Willis M, Neslusan C, Johansen P, Nilsson A, Asseburg C

“Impact of the Framingham Offspring Study (FOS) vs. Kaiser Permanente Northwest (KPNW) Prediction Equations for Diabetes Mellitus in Economic Modelling of T2DM”, Presented at EASD 51st Annual Meeting, Stockholm, Sweden, September 14-18, 2015, Asseburg C, Johansen P, Nilsson A, Willis M

Cost-Effectiveness of Canagliflozin (CANA) Versus Sitagliptin (SITA) as Add-on to Metformin plus Sulfonylurea in Patients with Type 2 Diabetes Mellitus (T2DM) in Brazil, Presented at ISPOR 5th Latin America Conference, Santiago, Chile, September 6-8, 2015, Pititto L, Neslusan C, Teschemaker AR, Johansen P, Willis M, Asano E, Puig A

“The Effect of Treatment Intensification Assumptions on Estimates of Cost-Effectiveness in Type 2 Diabetes Mellitus”, Presented at ISPOR 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 16-20, 2015, Willis M, Johansen P, Neslusan C

“The Cost-Effectiveness of Canagliflozin versus Saxagliptin Among Older Individuals Living with Type 2 Diabetes Mellitus in Canada”, Presented at ISPOR 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 16-20, 2015, Teschemaker AR, Neslusan C, Sabapathy S, Yoong K, Johansen P, Willis M

“The Cost-Effectiveness of Canagliflozin versus Sitagliptin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea in a Canadian Setting”, Presented at ISPOR 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 16-20, 2015, Sabapathy S, Neslusan C, Yoong K, Teschemaker AR, Johansen P, Willis M

“Impact of Weight-related Utilities on the Cost-Effectiveness of Canagliflozin versus Sitagliptin as Third-line Therapy in Type 2 Diabetes Mellitus in a Canadian Setting Presented at ISPOR 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 16-20, 2015, Sabapathy S, Neslusan C, Yoong K, Teschemaker AR, Johansen P, Willis M

“Time until Insulin Initiation for Canagliflozin versus Dapagliflozin in Dual and Triple Therapy for Type 2 Diabetes Mellitus (T2DM) in Ireland”, Presented at ISPOR 20th Annual Meeting, Philadelphia, Pennsylvania, USA, May 16-20, 2015, Bacon T, Willis M, Johansen P, Neslusan C

"The Cost-Effectiveness of Canagliflozin Versus Sulphonylurea in Patients With Type 2 Diabetes With Inadequate Control on Metformin Monotherapy in the United Kingdom", Presented at the Diabetes UK Professional Conference, London, U.K., March 11-15, 2015. Schroeder M, Johansen P, Willis M, Neslusan C

“The Cost-Effectiveness of Canagliflozin (CANA) versus Dapagliflozin (DAPA) in Patients with Type 2 Diabetes Mellitus (T2DM) with Inadequate Control on Metformin (MET) Monotherapy in the United Kingdom”, Presented at Presented at ISPOR 17th Annual European Congress, Amsterdam, Netherlands, November 8-12, 2014. Schroeder M, Johansen P, Thompson G, Neslusan C, Willis M

“Is Canagliflozin Cost-Effective Compared to Sitagliptin Across Multiple Lines of Type 2 Diabetes Mellitus Therapy in Ireland?” Presented at ISPOR 17th Annual European Congress, Amsterdam, Netherlands, November 8-12, 2014. Bacon T, Willis M, Johansen P, Neslusan C, Nuhoho S, Worbes-Cerezo M

“The Cost-Effectiveness of Canagliflozin Versus Liraglutide in Patients With Type 2 Diabetes Failing to Achieve Glycaemic Control on Metformin Monotherapy in Ireland”, Presented at Presented at ISPOR 17th Annual European Congress, Amsterdam, Netherlands, November 8-12, 2014. Bacon T, Willis M, Johansen P, Neslusan C, Nuhoho S, Worbes-Cerezo M

“The Cost-Effectiveness of Canagliflozin Versus Insulin-Secretagogues (Sulphonylureas) or Insulin in Patients With Type 2 Diabetes Mellitus as an Add-on to Metformin in Ireland”, Presented at Presented at ISPOR 17th Annual European Congress, Amsterdam, Netherlands, November 8-12, 2014. Bacon T, Willis M, Johansen P, Neslusan C, Nuhoho S, Worbes-Cerezo M

“The Cost-Effectiveness of Canagliflozin (CANA) versus Sitagliptin (SITA) as Third-Line Therapy in the Treatment of Type 2 Diabetes Mellitus in the U.K.”, Presented at EASD 50th Annual Meeting, Stockholm, Sweden, September 15-19, 2014 Thompson G, Schroeder M, Neslusan C, Willis M, Johansen P, Teschemaker A

“Cost-Effectiveness of Canagliflozin (CANA) versus Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the U.S., Presented at ADA 74th Scientific Sessions, San Francisco, CA, USA, June 13-17, 2014, Martin S, Neslusan C, Vo L, Teschemaker AR, Johansen P, Willis M.

“Cost-Effectiveness Analysis of Canagliflozin (CANA) Versus Maximally Titrated Glimepiride (GLIM) as an Add-on to Metformin (MET) in Patients With Type 2 Diabetes Mellitus (T2DM) in the United States”, Presented at ADA 74th Scientific Sessions, San Francisco, CA, USA, June 13-17, 2014, Neslusan C, Martin S, Teschemaker A, Vo L, Johansen P, Willis M.

“Cost-Effectiveness Analysis of Canagliflozin (CANA) versus Dapagliflozin (DAPA) as an Add-on to Metformin (MET) in Patients with Type 2 Diabetes Mellitus (T2DM in the United States”, Presented at ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31 – June 3, 2014, Neslusan C, Teschemaker A, Martin S, Willis M, Johansen P.

“The Impact of Alternative Estimates of Disutilities Associated with Hypoglycemia on Net QALY’s: Canagliflozin versus Sitagliptin as Add-on Therapy in Individuals with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on a Background of Metformin (MET) plus Sulfonylurea (SU) in the Canadian Setting”, Presented at ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31 – June 3, 2014. Yoong K, Willis M, Johansen P, Yim C, Teschemaker A, Neslusan C

“Sources of long-term quality adjusted life year (QALY) gains for Canagliflozin (CANA) versus Glimepiride (SU) in the treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting”, Presented at ISPOR 16th Annual European Congress, Dublin, Ireland, November 2-6, 2013. Girod I, Willis M, Johansen P, Schroeder M, Thompson G, Neslusan C.

“Sources of long-term quality adjusted life year (QALY) gains for Canagliflozin (CANA) versus Sitagliptin (SITA) in the treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting”, Presented at ISPOR 16th Annual European Congress, Dublin, Ireland, November 2-6, 2013. Willis M, Johansen P, Schroeder M, Thompson G, Girod I, Neslusan C.

“Impact of patient weight trajectory on cost-effectiveness assessment of treatments of Type 2 Diabetes Mellitus (T2DM)”, Presented at ISPOR 16th Annual European Congress, Dublin, Ireland, November 2-6, 2013. Schroeder M, Willis M, Johansen P, Girod I, Neslusan C, Thompson G.

“Assessment of the key drivers of cost-effectiveness in the economic modelling of Canagliflozin (CANA) versus glimepiride (SU) in the treatment of Type 2 Diabetes Mellitus (T2DM) in the UK setting”, Presented at ISPOR 16th Annual European Congress, Dublin, Ireland, November 2-6, 2013. Thompson G, Willis M, Johansen P, Neslusan C, Schroeder M, Girod I.

”A Health Economic Analysis of the Long-term Benefits and Associated Cost Offsets of Canagliflozin Dual Therapy in Mexico”, Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 4th Latin America Conference, Buenos Aires, Argentina, September 12-14, 2013. Cheryl Neslusan, Anna Teschemaker, Pierre Johansen, Michael Willis, Atanacio Valencia, Andrea Puig.

“A Health Economic Analysis of the Long-term Benefits and Associated Cost Offsets of Canagliflozin Monotherapy in the US”, Poster presentation at ADA 73rd Scientific Sessions, Chicago, IL, USA, June 21-25, 2013. Cheryl Neslusan, Pierre Johansen, Michael Willis, Silas Martin.

”The Importance of HbA1c Evolution in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus (T2DM)”, Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress, Berlin, Berlin, Germany, November 3-7, 2012. Michael Willis, Jianming He, Cheryl Neslusan, Pierre Johansen, Melany Worbes Cerezo.

“Effect of Modest Weight Loss on Long-term Health Outcomes in People Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) in Canada”, Poster presentation at the 2012 CDA/CSEM Professional Conference and Annual Meetings, Vancouver, Canada, October 10-13, 2012. Pierre Johansen, Anna R. Teschemaker, Nicole Brazier, Cheryl Neslusan, Michael Willis.

“The Health Impact of Getting to Glucose, Systolic Blood Pressure (SBP), and Serum Cholesterol Goals in People Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) in Canada”, Poster presentation at the 2012 CDA/CSEM Professional Conference and Annual Meetings, Vancouver, Canada, October 10-13, 2012. Anna R. Teschemaker, Pierre Johansen, Nicole Brazier, Cheryl Neslusan, Michael Willis.

“Economic and Health Outcomes (ECHO)-T2DM Model: Overview and Results of Validation Challenge”, Presented at Economics, Modelling and Diabetes: The Mt Hood 2012 Challenge, Baltimore, Maryland, USA, June 7-8, 2012. Michael Willis and Pierre Johansen, Christian Asseburg, Cheryl Neslusan and Jianming He.

© IHE 2017